NEWS AND UPDATES
May 2026
Dr. Henry Lee chaired a Round Table Discussion at CNS Discovery HubXchange in Boston.
Galibra presented pilot data on a novel gene therapy strategy for Drug Resistant Epilepsy at the ASGCT Annual Meeting in Boston.
Galibra was invited as an industrial partner and observer of the Global Gene’s RARE Advocate Development (RAD) Brain Workshop in Boston.
April 2026
Galibra achieved $1M ‘Friends and Family’ Round Fundraise.
March 2026
Amber Freed was featured in CNBC Cures Program.
Galibra was featured at LSX Miami.
Galibra was featured at 9th Gene Therapy Development Summit in Boston.
Galibra was featured at MedInvest Conference in NYC.
February 2026
Galibra received funding support from two individual investors.
January 2026
Galibra was featured at the JPM RESI Conference in San Francisco, as a Judges’ Pick recognizing ‘standout companies for exceptional science, compelling business models, and strong execution‘.
Brad Hoffman was appointed Chief Financial Officer of Galibra Neuroscience.
December 2025
Galibra was featured at the New England Venture Summit in Boston.
Galibra was featured in the cover story of the Life Sciences Review magazine.
Amber Freed was featured in an exclusive interview in People.com regarding her quest to create the world’s first treatment for her son.
Galibra was invited to present updates on SLC6A1 gene therapy and participated in a panel discussion in the SLC6A1 Symposium in Atlanta.
September 2025
Drs Pearl, Rotenberg, and Lee were featured at the International League Against Epilepsy (ILAE) Conference (Lisbon, Portugal) in a Special Interest Session titled ‘New Challenges and Progress in Treatment of Inherited Metabolic Epilepsies’.
Galibra was featured at the LSX World Congress 2025 in Boston.
Dr Phillip Pearl was featured in a recent podcast on his journey as a pediatric neurologist and recent advances in treatment for metabolic epilepsies.
Part 1: https://www.youtube.com/watch?v=yJ31k_6xNNg
Part 2: https://www.youtube.com/watch?v=scBYPashBAs
August 2025
Galibra was awarded an NIH STTR Award 1R41NS145933-01 titled ‘Developing Brain Penetrable AAV Gene Therapy for Succinic Semialdehyde Dehydrogenase Deficiency’.
Galibra announced licensing agreement with Apertura Gene Therapy using next-gen BBB-penetrating AAV capsid (CapX) for GAL005.
June 2025
Dr Alexander Rotenberg is named 2025 Harrington Scholar-Innovator Award recipient by the Harrington Discovery Institute, for his project titled ‘Gene therapy for a rare inherited disease, Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)’.
Galibra Neuroscience received additional funding support from a patient advocacy group.
May 2025
Dr Henry Lee presented work on SSADH-targeted gene replacement therapy and hosted a scientific session ‘Translational strategies for cell and gene therapies in inherited neurotransmitter disorders’ in the American Society of Gene & Cell Therapy (ASGCT) annual meeting in New Orleans.
April 2025
Galibra Neuroscience presented SSADH-targeted gene replacement therapy (GAL005) in the World Orphan Drug Congress USA in Boston.
March 2025
Galibra Neuroscience was featured at the Investival Showcase USA Event in Miami.
December 2024
Galibra Neuroscience presented at the SLC6A1 and CURE GABA-A Scientific Meetings in Los Angeles.
Dr Henry Lee presented in the Future Benchmarks of Epilepsy Care session and latest work on SSADH at the Annual Meeting of American Epilepsy Society in Los Angeles.
Dr Henry Lee was named one of the Young Investigators of the Rare Epilepsy Network 2024.
Amber Freed was featured in the Rare Documentary premiered at Harvard Medical School.
September 2024
Construction of an inducible GABA-T mouse model has begun.
July 2024
Dr Henry Lee discussed the key elements of developing gene therapies for inherited disorders of neurotransmission including SSADH deficiency in a podcast at JIMD.
May 2024
Dr Henry Lee presented our work on SSADH deficiency in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Baltimore.
Galibra Neuroscience obtained Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene supplement therapy for SLC6A1-related disorders.
April 2024
Dr Guangping Gao joined Galibra Neuroscience as AAV Manufacturing Consultant.
Brad Hoffman joined Galibra Neuroscience as Director of Business Development.
January 2024
Galibra Neuroscience received funding support from an individual investor.
December 2023
Our work on SSADH deficiency was featured in a poster highlight session in the American Epilepsy Society Annual Meeting in Orlando.
Amber Freed joined Galibra Neuroscience as Chief Development Officer.
Galibra Neuroscience obtained Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene replacement therapy for SSADH deficiency.
Dr Phillip Pearl joined Galibra Neuroscience as Clinical Study Consultant.
2023
Galibra Neuroscience was founded by Drs Alexander Rotenberg and Henry Lee.
